Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Expected annual number of new human papillomavirus (HPV)-related cancer cases in men in Europea

From: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

Cancer sites (ICD 10 code) Expected number of new cancer cases, irrespective of HPV status
(bounds)
HPV prevalence by site (%)
(95%CI)
Expected number of new cancer cases attributable to HPV
(bounds)
Prevalence of HPV 16/18 in HPV-positive cancers (%) Expected number of new cancer cases attributable to HPV16/18
Head and neck
Oral cavityb
Oropharynxc
Larynx (C32)
67,354
(63,443-71,292)
20,133
(18,768-21,514)
20,433
(19,651-21,776)
26,788
(25,210-28,382)
16.0
(13.4-18.8)
28.2d
(24.4-32.2)
21.3
(18.5-24.3) [18]
14,098
(11,455-17,077)
3,221
(2,515-4,045)
5,171
(5030-5311)
5,706
(4,664-6,897)
68.2/34.1
86.7/2.8
69.2/17.0
12,707
3,221
4,567
4,919
Anus (C21) 2,162
(1,722-2,620)
84.2
(81.5-86.9) [19]
1,821
(1,403-2,277)
87.1/6.2 1,699
Penis (C60) 3,178
(2,623-3,751)
46.7
(42.0-51.3) [20]
1,484
(1,102-1925)
60.2/13.4 1,091
Total 72,694
(67,957-77,470)
  17,403
(14,049-21,161)
  15,497
  1. ICD International Classification of Diseases, CI confidence interval
  2. a 26 European countries
  3. b Includes tongue (C01-02), mouth (C03-06), and also includes base of the tongue, which actually belongs to the oropharynx
  4. c Includes tonsil (C09), other oropharynx (C10), hypopharynx (C12-13) and pharynx unspecified (C14)
  5. d Except hypopharynx (C12-13), where HPV prevalence is the same as in laryngeal cancer (C32)